This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Delva, P. Articles by Lechi, A. Search for Related Content PubMed PubMed Citation Articles by Delva, P. Articles by Lechi, A. Related Collections Ion channels/membrane transport Other etiology

(Hypertension. 2000;35:113.)
© 2000 American Heart Association, Inc.

Scientific Contributions

Intralymphocyte Free Magnesium in Patients With Primary Aldosteronism

Aldosterone and Lymphocyte Magnesium Homeostasis

Pietro Delva; Caterina Pastori; Maurizio Degan; Germana Montesi; Paolo Brazzarola; Alessandro Lechi

From the Departments of Biomedic and Surgical Sciences (P.D., C.P., M.D., G.M., A.L.) and Surgery (P.B.), University of Verona, Policlinico Borgo Roma, Verona, Italy.

Correspondence to Dr Pietro Delva, Medicina Interna C, Università di Verona, Policlinico Borgo Roma, 37134 Verona, Italy. E-mail delvap{at}borgoroma.univr.it

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Abstract—It is known that hyperaldosteronism has been associated with magnesium deficiency, yet there are no data on the intracellular concentration of ionized magnesium ([Mg²⁺_i]) in subjects with primary aldosteronism (PA). We measured intralymphocyte free magnesium ([Mg²⁺_i]) and intralymphocyte free calcium ([Ca²⁺_i]) in 16 patients with PA and 26 normotensive control subjects (NCs). [Mg²⁺_i] and [Ca²⁺_i] were also measured in blood lymphocytes incubated in vitro with aldosterone, according to a fluorimetric method. In subjects with PA, [Mg²⁺_i] was significantly lower than that in NCs (mean±SD; PA 203±56 µmol/L, NCs 291±43 µmol/L, 95% confidence interval 57 to 119, P=0.001). In the patients, [Ca²⁺_i] did not prove to be statistically different from that of NCs (mean±SD; PA 47.2±10.6 nmol/L, NCs 53.2±11 nmol/L). The lymphocytes exposed to the action of aldosterone showed a significant reduction in [Mg²⁺_i] (n=15, NCs 271±28 µmol/L, aldosterone treatment 188±39 µmol/L, P=0.001, 95% confidence interval 57 to 108). The dose-effect curve of aldosterone on [Mg²⁺_i] showed an EC₅₀ value of 0.5 to 1 nmol/L aldosterone. The reduction in [Mg²⁺_i] mediated by aldosterone is antagonized by the receptor inhibitor of aldosterone; it is inhibited by inhibitors of protein synthesis and is not measurable when the lymphocytes are incubated in an Na⁺-free medium. The data are consistent with the hypothesis that aldosterone affects the cellular homeostasis of magnesium, probably through modification of the activity of the Na⁺-Mg²⁺ antiporter.

Key Words: aldosterone • ions • magnesium • calcium • lymphocytes • hypertension

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
Primary aldosteronism is a volume-dependent form of hypertension that is the subject of increasing interest. Studies aim to elucidate the cellular events resulting from in vivo aldosterone action. With regard to ion membrane transport systems, an increased activity of membrane Na⁺-H⁺ exchanger^{1 2} and increased plasma amounts of an Na⁺-K⁺ pump inhibitor have been described in primary aldosteronism.³

It has long been known that cases of hyperaldosteronism are characterized by magnesium deficiency, yet the data that could explain this phenomenon are extremely limited and contrasting and refer exclusively to levels of plasma and urinary magnesium. This is a limiting factor when we consider the fact that >99% of total body magnesium is located intracellularly.

Aldosterone is believed to influence renal magnesium handling, causing magnesium wasting,⁴ although there is disagreement regarding this finding.⁵ The acute administration of mineralocorticoids fails to modify magnesium and calcium excretion in humans,⁵ but certain clinical and experimental data suggest that the excretion of calcium and magnesium may be affected by the long-term action of mineralocorticoids.⁴ It has also been suggested that magnesium operates as a regulator of the production of aldosterone. Indeed, the infusion of magnesium suppresses plasma aldosterone levels in humans,^{6 7} high levels of magnesium decrease aldosterone production in cultures of rat zona glomerulosa cells,⁸ and experimental magnesium deficiency stimulates aldosterone production.

Very little data are available on plasma magnesium in subjects with primary aldosteronism. In 1954, Mader and Iseri⁹ reported the case of a patient with corticosterone-like mineralocorticoid hypersecretion with hypomagnesemia. In 1962, Horton and Biglieri⁴ described the cases of 5 patients with primary aldosteronism and an increased renal magnesium clearance despite normal plasma magnesium levels. More recently, Resnick and Laragh¹⁰ described the cases of 10 patients with primary aldosteronism who had normal plasma magnesium values.

There also are no data concerning the possible effects of aldosterone on the cellular homeostasis of magnesium; thus, no data are available so far relating [Mg²⁺_i] in patients with primary aldosteronism and the in vitro cellular effects of aldosterone on Mg²⁺_i.

This lack of data has mainly been due to technical limitations in the measurement of intralymphocyte free magnesium concentration ([Mg²⁺_i]). The synthesis of a new fluorescent magnesium-sensitive dye¹¹ has allowed the measurement of [Mg²⁺_i] in nucleated cells.¹² The use of this technique has made possible the discovery of a lack of Mg²⁺_i in subjects with plurimetabolic syndrome,¹³ suggesting a relationship with peripheral resistance to insulin,¹⁴ whereas in a group of patients with essential hypertension, any abnormalities in [Mg²⁺_i] could be detected.¹²

We therefore measured [Mg²⁺_i] in a group of 16 patients with primary aldosteronism and a group of 26 normotensive control subjects. Lymphocytes are used because of their simple availability. There is no logical relation to the measured parameters, but several studies suggest that the magnesium content of white blood cells represents a reliable indicator of magnesium status. Intralymphocyte free calcium concentration ([Ca²⁺_i]) was also measured, mainly to exclude substantial Ca²⁺_i variations, which theoretically may affect magnesium determinations¹⁵ ; in addition, no data on Ca²⁺_i in this pathological condition are available.

Finally, we studied the in vitro action of aldosterone on [Mg²⁺_i] and [Ca²⁺_i] in human lymphocytes.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
[Mg²⁺_i] and [Ca²⁺_i] were measured in 16 patients with primary aldosteronism (6 with adrenal adenoma and 10 with adrenal hyperplasia) and in 26 normotensive healthy subjects with no family history of hypertension who were recruited from hospital medical and paramedical staff. Patients with primary aldosteronism and normotensive control subjects were not matched for gender because there is no evidence of gender-dependent [Mg²⁺_i] and [Ca²⁺_i] differences.¹² After hospitalization, the diagnosis of primary aldosteronism was made for all the patients on the basis of a complete clinical, laboratory, and instrumental examination. The diagnosis of primary aldosteronism caused by aldosterone-producing adenomas or bilateral adrenal hyperplasia was made with the use of computed tomography scanning and bilateral adrenal vein sampling. In this way, we sought to detect aldosterone, renin, and cortisol levels; the latter was used to confirm the accuracy of catheter placement in the adrenal vein. Particular care was taken to exclude patients with chronic alcoholism and diabetes because these 2 pathological conditions are associated with magnesium wasting.^{16 17} The study was approved by the local ethics committee, and the subjects gave informed consent.

The blood samples used for the determination of lymphocyte [Mg²⁺_i] and [Ca²⁺_i] were taken from patients and control subjects in the morning after overnight fasting. All forms of drug treatment were discontinued 3 weeks before the samples were taken. Because diuretics are known to affect Mg²⁺_i levels,¹⁸ patients receiving such treatment at any time were excluded from the study. All subjects were on an unrestricted diet.

Routine Laboratory Tests
Total plasma calcium, sodium, and potassium levels were measured with an autoanalyzer (Technicon DAX 96; Miles Inc), as were total plasma magnesium and calcium levels (Hitachi 911 Analyzer; Hitachi Ltd). Total urinary magnesium and calcium, sodium, and potassium levels were measured with the use of flame photometry. Plasma renin, aldosterone concentration, and urinary aldosterone were measured with radioimmunoassay.^{19 20}

Measurement of [Mg²⁺_i] and [Ca²⁺_i]
We used the method previously described.¹² Briefly, peripheral blood lymphocytes were isolated through Ficoll sedimentation, resulting in cell preparations with a percentage of lymphocytes of >97%. Three separate aliquots of lymphocytes (6x10⁶ each) were treated with 10 µmol/L Furaptra acetoxymethyl ester (Molecular Probes) to measure [Mg²⁺_i] or with Fura-2 acetoxymethyl ester (5 µmol/L) to measure [Ca²⁺_i].^{12 21} For [Mg²⁺_i] determinations, fluorescence emission at 510 nm was measured with alternate excitation at 335 and 370 nm within a thermostatically controlled cuvette holder (31°C) in an Hitachi F-2000 fluorescence spectrophotometer. We used the intracellular cation concentration that was the mean of the concentrations of 3 separate experiments. The transmembrane leak of fluorescence probe was reduced by limiting the temperature to 31°C. Interference with the reading by residual probe leakage was eliminated by the addition of EGTA and EDTA. Calibration was performed after cell lysis with Triton-X. The intra-assay and interassay variability (coefficient of variation) determinations were 5.8 and 3.9 for Mg²⁺ and 4.6 and 12.7 for Ca²⁺, respectively.

In Vitro Study of Effects of Aldosterone on [Mg²⁺_i] and [Ca²⁺_i]
The lymphocytes used for these tests were from healthy donors chosen from the medical staff. The measurement of [Mg²⁺_i] and [Ca²⁺_i] was carried out according to the procedures described earlier. To limit the possibility of artifacts, the hormones tested in vitro on the lymphocytes were not added directly to the test-tube during reading from the spectrofluorometer. We chose another strategy, which involved isolation of the lymphocytes with Ficoll and the subsequent conduction of 2 or more parallel experiments with cells from the same donor, which were incubated with only the vehicle of the hormone (control) or the hormone, respectively.

Statistical Analysis
Results are expressed as mean±SD. Because no evidence of non-normal distribution or inequality of variances was present in the variables considered, comparison between groups was performed with Student’s t test and considered statistically significant when the probability of the null hypothesis was 5%. Confidence intervals for differences in mean values were also provided. To determine differences between groups, a 1-way ANOVA was used. Correlations between 2 variables were studied with the use of the linear regression method.

	Results

Top Abstract Introduction Methods Results Discussion References

 
Main Clinical and Metabolic Variables
Total plasma magnesium, daily urinary magnesium excretion, and total plasma calcium did not differ significantly between patients with primary aldosteronism and normotensive controls (Table). Plasma potassium and plasma renin levels in the upright position were significantly reduced in patients with primary aldosteronism compared with normotensive control subjects. Plasma aldosterone levels in the upright position together with daily urinary aldosterone excretion were significantly increased in patients with primary aldosteronism compared with normotensive control subjects.

View this table: [in this window] [in a new window]   Table 1. Main Clinical and Metabolic Variables in Study Subjects

[Mg²⁺_i] in Patients With Primary Aldosteronism and Normotensive Subjects
Individual values for [Mg²⁺_i] in essential hypertensive patients and normotensive control subjects are shown in Figure 1. Mean values are significantly lower (P=0.000001) in patients with primary aldosteronism (mean±SD 203±56 µmol/L) than in normotensive control subjects (291±43 µmol/L; 95% confidence interval 57 to 119). Patients with adenoma had [Mg²⁺_i] values not statistically different from those of patients with adrenal hyperplasia (mean±SD; adenoma n=6, 199±65 µmol/L; hyperplasia n=10, 204±59 µmol/L).

View larger version (20K): [in this window] [in a new window]   Figure 1. Values of [Mg2+i] in patients with primary aldosteronism (n=16) and normotensive control subjects (n=26). indicates patients with adenoma; , patients with hyperplasia.

[Ca²⁺_i] in Patients With Primary Aldosteronism and Normotensive Subjects
Mean values for [Ca²⁺_i] were not significantly different between patients with primary aldosteronism (mean±SD 47.2±10.6 nmol/L) and normotensive control subjects (53.2±11 nmol/L). Patients with adenoma had [Ca²⁺_i] values that were not statistically different from those of patients with adrenal hyperplasia (adenoma n=6, 44±4 nmol/L; hyperplasia n=10, 45±14 nmol/L).

Correlations Between [Mg²⁺_i] and Clinical and Metabolic Variables
In univariate regression in patients with primary aldosteronism, [Mg²⁺_i] did not correlate with any of the following variables: age (r=0.120), systolic and diastolic blood pressures (r=0.544 and 0.540, respectively), plasma total magnesium (r=0.025), urinary total magnesium (r=-0.347), plasma renin concentration in upright and standing positions (r=0.360 and 0.338, respectively), plasma aldosterone in upright and standing positions (r=0.235 and 0.237, respectively), plasma potassium (r=0.196), and length of history of hypertension (r=0.007).

[Mg²⁺_i] and [Ca²⁺_i] in Lymphocytes Exposed In Vitro to Aldosterone and Related Steroid Hormones
Lymphocytes exposed in vitro to the action of aldosterone (1 µmol/L) for 100 minutes showed a significant decrease in [Mg²⁺_i] (n=15, mean±SD; controls 271±28 µmol/L, aldosterone treatment 188±39 µmol/L; P=0.0000003; 95% confidence interval 57 to 108). Figure 2 shows the time course of action of aldosterone on these cells. The effect is visible after 30 minutes and reaches a maximum level after 2 hours, after which it remains more or less stable until the fifth hour. After 5 hours, the fall in [Mg²⁺_i] is equal to 50% of the initial level.

View larger version (16K): [in this window] [in a new window]   Figure 2. Time course of effect of aldosterone on [Mg2+i].

Figure 3 shows the effect of aldosterone (1 µmol/L) on the decrease in [Mg²⁺_i] is completely antagonized by canrenoic acid (15 µmol/L) and by inhibitors of transcription (50 µg/mL actinomycin D) and protein synthesis (15 µg/mL cycloheximide) (mean±SD; controls n=6, 100±8%; aldosterone n=6, 63±8%; aldosterone and canrenoic acid n=6, 99±6%; aldosterone and cycloheximide n=6, 98±7%; aldosterone and actinomycin D n=6, 98±6%). Figure 4 shows the dose-effect curves of the decrease in [Mg²⁺_i] in response to the effect of 3 steroid hormones with 21 carbon atoms: aldosterone, cortisol, and progesterone. The dose-effect curve for aldosterone shows there is a strong dependence of [Mg²⁺_i] on aldosterone concentration; and the half-maximal effect of aldosterone (EC₅₀) occurs at a concentration of 0.5 to 1 nmol/L aldosterone. Progesterone and cortisol (Figure 4) have a negligible effect on [Mg²⁺_i], as shown by its relative EC₅₀ values (100 nmol/L and 10 nmol/L, respectively). If we incubate the lymphocytes in a sodium-free medium, the levels of [Mg²⁺_i] are much higher because the efflux of Na⁺-dependent magnesium is inhibited. Under these conditions, the decrease in [Mg²⁺_i] produced by the aldosterone is not measurable (Na⁺ medium n=6, 236±18 µmol/L; Na⁺ medium and 1 µmol/L aldosterone n=6, 161±10 µmol/L [P=0.003]; Na⁺-free medium n=6, 577±147 µmol/L; Na⁺-free medium and 1 µmol/L aldosterone n=6, 587±96 µmol/L [NS]).

View larger version (28K): [in this window] [in a new window]   Figure 3. In vitro effect of aldosterone is completely antagonized by canrenoic acid, a specific aldosterone receptor antagonist. Actinomycin D and cycloheximide, inhibitors of transcription and protein synthesis, respectively, completely reverse the effect of aldosterone on [Mg2+i].

View larger version (22K): [in this window] [in a new window]   Figure 4. Dose-effect curves of effects of aldosterone, progesterone, and cortisol on [Mg2+i].

Finally, we measured [Ca²⁺_i] in lymphocytes incubated in vitro with 1 µmol/L aldosterone for 100 minutes. We did not find any statistically significant difference in [Ca²⁺_i] from the control cells (n=6, controls 47±6 nmol/L, aldosterone treatment 53±6 nmol/L, NS).

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
Primary aldosteronism represents an interesting model for the study of the physiopathology of aldosterone. The in vivo influence of aldosterone on Mg²⁺_i has been hypothesized, but cellular measurements have not been performed. Aldosterone is thought to act at renal level through the inducement of renal tubular magnesium excretion,⁴ although this is still a matter of debate.⁵ This probably occurs secondary to the volume expansion and hypertension associated with hyperaldosteronism because magnesium reabsorption is related to tubular flow rates and sodium reabsorption, both of which are altered in this situation. Horton and Biglieri described significantly increased magnesiuria in patients with primary aldosteronism,⁴ but other authors have not confirmed these findings.⁵ In our group of patients, daily urinary magnesium excretion was not statistically different from that of control subjects.

Regarding magnesium plasma levels, most data from the literature indicate that they are not significantly altered in patients with primary aldosteronism,^{4 10} and our results are in accordance with previous data. Despite this fact, Resnick and Laragh¹⁰ reported that although serum magnesium values in their subjects with primary aldosteronism were within normal limits, they were significantly higher than those in normotensive control subjects. They believe that this is in keeping with the hypothesis that low-renin hypertension has a distinctive magnesium and calcium profile.²² We must point out that Resnick et al²² refer to plasma ionized magnesium as opposed to plasma total magnesium, which was measured in the present study. Despite a modest overlap, we found that mean [Mg²⁺_i] is significantly lower in patients with primary aldosteronism than in normotensive control subjects. Three of 16 patients were characterized by normal [Mg²⁺_i], but the majority of the patients showed a significant decrease in ionized magnesium. No significant differences were found between patients with adrenal hyperplasia and patients with aldosterone-producing adenomas.

From these data on patients with primary aldosteronism, it is not possible to explain the physiopathological mechanism underlying the Mg²⁺_i deficiency. In particular, we were not able to demonstrate any significant correlation between [Mg²⁺_i] and renal magnesium excretion or with renin or aldosterone plasma and urinary levels, and we can neither confirm nor exclude a cause-effect relationship.

In consideration of the questions raised by these ex vivo results, we studied the effect in vitro of aldosterone on lymphocytes. In vitro, aldosterone decreases the content of basal ionized magnesium by 45% to 50%, which is a highly significant reduction. The effect of aldosterone appears to be mediated by the specific receptor of the hormone in that the decrease in [Mg²⁺_i] is not observed when canrenoic acid, a specific antagonist of the receptor, is present. Moreover, the effect of the hormone seems to involve the classic genomic pathway of steroid action because it is completely eliminated by actinomycin D and cycloheximide, inhibitors of transcription and protein synthesis, respectively. The effects of aldosterone on the intralymphocyte contents of ionized magnesium appear to be dose dependent with an EC₅₀ value of 0.5 to 1 nmol/L aldosterone. This value is close the physiological concentration of plasmatic aldosterone (0.5 nmol/L) and suggests that aldosterone may play a role as physiological regulator of the Mg²⁺_i content. Cortisol and progesterone, which were tested because of their close biochemical similarity, also reduce [Mg²⁺_i] but only at higher concentrations, as shown by their respective EC₅₀ values, which appear to be higher than that of aldosterone. Finally, the experiments carried out without extracellular sodium suggest a possible mechanism through which the cellular action of aldosterone operates. In fact, in the absence of sodium on the outside of the plasmatic membrane, the activity of the Na⁺-Mg²⁺ antiporter, the principal known mechanism of magnesium efflux,²³ is inhibited. Under these conditions, the action of aldosterone is no longer measurable. The action of aldosterone on [Mg²⁺_i] therefore takes place exclusively in the presence of extracellular sodium, probably through the activation of a transport mechanism that decreases [Mg²⁺_i] by producing a Mg²⁺ efflux.

We consider these in vitro data concerning the effects of aldosterone on Mg²⁺_i to suggest an explanation of the mechanism that leads to the lack of Mg²⁺_i in patients with primary hyperaldosteronism. It seems probable that aldosterone directly affects the cell and modifies the cellular homeostasis of magnesium, probably through modification of the activity of the Na⁺-Mg²⁺antiporter of the plasmatic membrane. There seems to be a different mechanism to explain the negative magnesium balance in cases of hyperaldosteronism, an alternative to the hypothesis that attributes the stimulus to increase renal clearance of the ion to the chronic volume expansion.⁵ Moreover, the EC₅₀ values found for the effect of aldosterone on [Mg²⁺_i] could suggest that aldosterone has a role of physiological regulator of the [Mg²⁺_i].

A decrease in [Mg²⁺_i] may play a role in the pathogenesis of arterial hypertension in primary aldosteronism in that it is well known that in vitro magnesium deficiency is followed by an increase in vascular tone and potentiates the pressor effect of angiotensin II.²⁴ Despite this fact, the link between magnesium homeostasis and blood pressure regulation remains controversial.

Finally, although it was not the principal issue of our study, we measured total plasma calcium as well as [Ca²⁺_i]. We did not find any statistically significant differences in total calcium plasma levels and [Ca²⁺_i] between patients with primary aldosteronism and normotensive control subjects. Our results, which are limited to total calcium plasma levels, are in agreement with those of Resnick and Laragh.¹⁰

In conclusion, we have shown, for the first time, an Mg²⁺_i deficiency in patients with primary aldosteronism. Moreover, this hormone shows in vitro a specific effect on the cell model by significantly decreasing [Mg²⁺_i] via a mechanism that is probably genomic. It is therefore possible to hypothesize that the magnesium deficiency found in subjects with primary hyperaldosteronism is related to a direct effect of aldosterone on the cells. Furthermore, the EC₅₀ value for the action of aldosterone on [Mg²⁺_i] suggests that aldosterone may play a role as physiological regulator of the Mg²⁺_i content.

	Acknowledgments

 
This work was supported by grants from Ministero dell’Università e Ricerca Scientifica e Tecnologica (Italy) (MURST funds 40% and 60%) and Ricerca Sanitaria Finalizzata-Regione del Veneto (Italy).

Received May 5, 1999; first decision June 24, 1999; accepted August 27, 1999.

	References

Top Abstract Introduction Methods Results Discussion References

 

1. Delva P, Pastori C, Degan M, Montesi G, Bassi A, Lechi A. Erythrocyte Na-H exchanger and Na-Li countertransport activity in primary aldosteronism. Eur J Clin Invest. 1994;24:794–798.[Medline] [Order article via Infotrieve]
2. Koren W, Postnov IY, Postnov YV. Increased Na-H exchange in red blood cells of patients with primary aldosteronism. Hypertension. 1997;29:587–591.[Abstract/Free Full Text]
3. Delva P, Fallo F, Mantero F, Capra C, Degan M, Minuz P, Lechi A. Plasma levels of ouabain-like factor in primary aldosteronism. J Hypertens. 1987;5(suppl 5):s95–s97.
4. Horton R, Biglieri EG. Effect of aldosterone on the metabolism of magnesium. J Clin Endocrinol. 1962;22:1187–1192.
5. Massry SG, Coburn JW, Chapman LW, Kleeman CR. The acute effect of adrenal steroids on the interrelationship between the renal excretion of sodium, calcium and magnesium. J Lab Clin Med. 1967;70:563–570.[Medline] [Order article via Infotrieve]
6. Kisch ES, Dluhy RG, Williams GH. Regulation of renin release by calcium and ammonium ions in normal man. J Clin Endocrinol Metab. 1976;43:1343–1350.[Abstract]
7. Ichihara A, Suzuki H, Saruta T. Effects of magnesium on the renin-angiotensin-aldosterone system in human subjects. J Lab Clin Med. 1993;122:432–440.
8. Atarashi K, Matsuoka H, Takagi M, Sugimoto T. Magnesium ion: a possible regulator of aldosterone production. Life Sci. 1989;44:1483–1489.[Medline] [Order article via Infotrieve]
9. Mader IJ, Iseri LT. Spontaneous hypopotassemia, hypomagnesemia, alkalosis and tetany due to hypersecretion of corticosterone-like mineralocorticoid. Am J Med. 1955;December:976–988.
10. Resnick LM, Laragh JH. Calcium metabolism and parathyroid function in primary aldosteronism. Am J Med. 1985;78:385–390.[Medline] [Order article via Infotrieve]
11. Raju B, Murphy E, Levy LA, Hall RD, London RE. A fluorescent indicator for measuring cytosolic free magnesium. Am J Physiol. 1989;256:C540–C548.[Abstract/Free Full Text]
12. Delva P, Pastori C, Degan M, Montesi G, Lechi A. Intralymphocyte free magnesium in a group of patients with essential hypertension. Hypertension. 1996;28:433–439.[Abstract/Free Full Text]
13. Delva P, Pastori C, Degan M, Montesi G, Lechi A. Intralymphocyte free magnesium and plasma triglycerides. Life Sci. 1998;62:2231–2240.[Medline] [Order article via Infotrieve]
14. Delva P, Pastori C, Montesi G, Degan M, Micciolo R, Paluani F, Lechi A. Intralymphocyte free magnesium and calcium and insulin tolerance test in a group of essential hypertensive patients. Life Sci. 1998;63:1405–1415.[Medline] [Order article via Infotrieve]
15. Hurley TW, Ryan MP, Brinck RW. Changes of cytosolic Ca²⁺ interfere with measurements of cytosolic Mg²⁺ using mag-fura-2. Am J Physiol. 1992;263:C300–C307.[Abstract/Free Full Text]
16. Mendelson JH, Barnes B, Mayman C, Victor M. The determination of exchangeable magnesium in alcoholic patients. Metabolism. 1965;14:88–98.[Medline] [Order article via Infotrieve]
17. Mather HM, Nishet JA, Burton GH, Poston G, Bland JM, Bailey PA, Pilkington TR. Hypomagnesemia in diabetes. Clin Chim Acta. 1979;95:235–242.[Medline] [Order article via Infotrieve]
18. Sheehan J, White A. Diuretic-associated hypomagnesemia. Br Med J. 1982;285:1157–1159.
19. Wathen LK, Wuorala KW, Wathen MW. Validation of an immunoradiometric assay to measure plasma levels of active renin. J Clin Lab Anal. 1982;5:284–292.
20. Dujaili EAS, Edwards CRW. The development and application of a direct radioimmunoassay for plasma aldosterone using ¹³¹I-labelled ligand: comparison of three methods. J Clin Endocrinol Metab. 1978;46:105.[Abstract]
21. Grynkiewicz G, Poenie M, Tsien RY. A new generation of Ca²⁺ indicators with greatly improved fluorescence properties. J Biol Chem. 1985;260:3440–3450.[Abstract/Free Full Text]
22. Resnick LM, Laragh JH, Sealey JE, Alderman MH. Divalent cations in essential hypertension. N Engl J Med. 1983;309:888–891.[Abstract]
23. Gunther T, Vormann J., Hollriegl V. Characterization of Na⁺-dependent Mg²⁺ efflux from Mg²⁺-loaded erythrocytes. Biochem Biophys Acta. 1990;1023:455–461.[Medline] [Order article via Infotrieve]
24. Altura BM, Altura BT. Magnesium and contraction of arterial smooth muscle. Microvasc Res. 1974;7:145–155.[Medline] [Order article via Infotrieve]

This article has been cited by other articles:

				Y. Sun, R. A. Ahokas, S. K. Bhattacharya, I. C. Gerling, L. D. Carbone, and K. T. Weber Oxidative stress in aldosteronism Cardiovasc Res, July 15, 2006; 71(2): 300 - 309. [Abstract] [Full Text] [PDF]

				V. S. Chhokar, Y. Sun, S. K. Bhattacharya, R. A. Ahokas, L. K. Myers, Z. Xing, R. A. Smith, I. C. Gerling, and K. T. Weber Hyperparathyroidism and the Calcium Paradox of Aldosteronism Circulation, February 22, 2005; 111(7): 871 - 878. [Abstract] [Full Text] [PDF]

				Y. He, G. Yao, C. Savoia, and R. M. Touyz Transient Receptor Potential Melastatin 7 Ion Channels Regulate Magnesium Homeostasis in Vascular Smooth Muscle Cells: Role of Angiotensin II Circ. Res., February 4, 2005; 96(2): 207 - 215. [Abstract] [Full Text] [PDF]

				R. A. Ahokas, Y. Sun, S. K. Bhattacharya, I. C. Gerling, and K. T. Weber Aldosteronism and a Proinflammatory Vascular Phenotype: Role of Mg2+, Ca2+, and H2O2 in Peripheral Blood Mononuclear Cells Circulation, January 4, 2005; 111(1): 51 - 57. [Abstract] [Full Text] [PDF]

				V. S. Chhokar, Y. Sun, S. K. Bhattacharya, R. A. Ahokas, L. K. Myers, Z. Xing, R. A. Smith, I. C. Gerling, and K. T. Weber Loss of bone minerals and strength in rats with aldosteronism Am J Physiol Heart Circ Physiol, November 1, 2004; 287(5): H2023 - H2026. [Abstract] [Full Text] [PDF]

				K. T. Weber Furosemide in the long-term management of heart failure: The good, the bad, and the uncertain J. Am. Coll. Cardiol., September 15, 2004; 44(6): 1308 - 1310. [Full Text] [PDF]

				K. T. Weber From Inflammation to Fibrosis: A Stiff Stretch of Highway Hypertension, April 1, 2004; 43(4): 716 - 719. [Full Text] [PDF]

				R. A. Ahokas, K. J. Warrington, I. C. Gerling, Y. Sun, L. A. Wodi, P. A. Herring, L. Lu, S. K. Bhattacharya, A. E. Postlethwaite, and K. T. Weber Aldosteronism and Peripheral Blood Mononuclear Cell Activation: A Neuroendocrine-Immune Interface Circ. Res., November 14, 2003; 93 (10): e124 - e135. [Abstract] [Full Text] [PDF]

				K. T Weber, Yao Sun, L. A Wodi, A. Munir, E. Jahangir, R. A Ahokas, I. C Gerling, A. E Postlethwaite, and K. J Warrington Toward a broader understanding of aldosterone in congestive heart failure Journal of Renin-Angiotensin-Aldosterone System, September 1, 2003; 4(3): 155 - 163. [Abstract] [PDF]

				I. C. Gerling, Y. Sun, R. A. Ahokas, L. A. Wodi, S. K. Bhattacharya, K. J. Warrington, A. E. Postlethwaite, and K. T. Weber Aldosteronism: an immunostimulatory state precedes proinflammatory/fibrogenic cardiac phenotype Am J Physiol Heart Circ Physiol, July 11, 2003; 285(2): H813 - H821. [Abstract] [Full Text] [PDF]

				Y. Sun, J. Zhang, L. Lu, S. S. Chen, M. T. Quinn, and K. T. Weber Aldosterone-Induced Inflammation in the Rat Heart : Role of Oxidative Stress Am. J. Pathol., November 1, 2002; 161(5): 1773 - 1781. [Abstract] [Full Text] [PDF]

				R. M. Touyz, C. Mercure, and T. L. Reudelhuber Angiotensin II Type I Receptor Modulates Intracellular Free Mg2+ in Renally Derived Cells via Na+-dependent Ca2+-independent Mechanisms J. Biol. Chem., April 20, 2001; 276(17): 13657 - 13663. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Delva, P. Articles by Lechi, A. Search for Related Content PubMed PubMed Citation Articles by Delva, P. Articles by Lechi, A. Related Collections Ion channels/membrane transport Other etiology